Surging Demand for Antibody Drug Conjugates Driving the ADC Contract Manufacturing Market
The global ADC contract manufacturing market is estimated to be worth $1.79 billion in 2024 and is expected to grow at a CAGR of 13% during the forecast period, reaching ~$6.87 billion by 2035. The study consists of industry trends, detailed market analysis, service provider landscape, competitiveness landscape, recent expansions, partnerships and collaborations, capacity analysis, clinical trial analysis, likely partner analysis, demand analysis, value chain analysis, market impact analysis, and market forecast and opportunity analysis. The growth in the ADC contract manufacturing market size over the next decade is likely to be the result of anticipated increase in demand for antibody drug conjugates.
In recent years, antibody drug conjugates (ADC) have emerged as a potent class of therapeutics targeting a wide range of cancers including solid tumors and hematological tumors. These complex molecules consist of an antibody, which is attached to biologically active, cytotoxic agents through chemical linkers. ADC therapeutics possess enhanced stability, target specificity, tumor selectivity and pharmacokinetic properties. These properties have supported extensive research and development initiatives being undertaken for the advancement of ADC therapies to the market. In this context, the current ADC pipeline features the presence of over 260 candidates being evaluated in clinical trials, along with 23 ADC therapeutic programs that have already been approved by various regulatory agencies. The potential of such therapies in selectively targeting tumor cells, while limiting off target toxicities have paved the way for their success and widespread application in the healthcare industry.
However, the ADC manufacturing process is highly complex and is fraught with several challenges, including drug / linker side reactions, exposure to toxicity, contamination and up-scaling. Additionally, the manufacturing process requires significant expertise and use of cutting-edge technologies, which are highly cost intensive. Therefore, the ADC developers prefer outsourcing the manufacturing operations to ADC contract manufacturers. With an intent of cost saving, ADC therapy developers are continually utilizing the experience, capabilities and manufacturing facilities available with the contract manufacturing organizations in order to support their manufacturing operations. Further, it is worth mentioning that the CMOs engaged in ADC contract manufacturing are actively undertaking initiatives to become one-stop shops and mitigate the challenges associated with technology transfer and scale-up. Considering the increasing demand for ADCs and the increasing preference for outsourcing operations by drug developers, the ADC contract manufacturing market is likely to witness substantial market growth during the forecast period.
ADC Contract Manufacturing Market Share Insights
The market research report presents an in-depth analysis of the various companies that are engaged in the global ADC contract manufacturing market, across different segments, as defined below:
- Historical Trend: 2019-2021
- Base Year: 2022-2023
- Forecast Period: 2024-2035
- Market Size in 2024: $1.79 Billion
- CAGR: 13%
- Stage of Development
- Phase I
- Phase II
- Phase III
- Commercial
- Process Component
- Antibody
- HPAPI / Cytotoxic Payload
- Conjugation / Linker
- Fill / Finish
- Target Indication
- Solid Tumors
- Hematological Tumors
- Others
- Antibody Generation
- Second Generation
- Third Generation
- Fourth Generation
- Next Generation
- Antibody Origin
- Humanized
- Chimeric
- Murine
- Others
- Antibody Isotype
- IgG1
- IgG4
- Others
- Type of Payload
- Auristatin
- Camptothecin
- DNA Topoisomerase I Inhibitor
- Maytansinoid
- Others
- Type of Linker
- Maleimide
- SMCC
- Tetrapeptide-based linker
- Valine-citrulline
- Others
- Key Geographical Regions
- North America
- Europe
- Asia-Pacific and Rest of the World
- Key Companies Profiled
- AbbVie Contract Manufacturing
- Abzena
- CARBOGEN AMCIS
- Catalent Pharma Solutions
- Cerbios-Pharma
- Formosa Laboratories
- GBI
- Lonza
- MabPlex
- Millipore Sigma
- Piramal Pharma Solutions
- Sterling Pharma Solutions
- WuXi Biologics
- (Full list of 30 companies captured is available in the report)
- PowerPoint Presentation (Complimentary)
- Customization Scope: 15% Free Customization
- Excel Data Packs (Complimentary)
- Market Landscape
- Company Competitiveness Analysis
- Recent Expansions
- Partnerships and Collaborations
- Capacity Analysis
- Clinical Trial Analysis
- Likely Partner Analysis
- Demand Analysis
- Market Forecast and Opportunity Analysis
ADC Contract Manufacturing Market Segmentation Overview
Market Share by Stage of Development
Based on the stage of development, the global ADC contract manufacturing market is categorized into phase I, phase II, phase III and commercial. The commercial segment occupies the highest share in 2023 and is expected to witness substantial growth in the coming years.
Market Share by Type of Component
Based on the type of component, the global antibody drug conjugates contract manufacturing market is categorized into antibody, HPAPI / cytotoxic payload, conjugation / linker and fill / finish. The antibody segment occupies the highest share in 2023 in the overall ADC contract manufacturing market and this trend is expected to remain same during the forecast period. This can be primarily attributed to the fact that antibody manufacturing is a time and cost-intensive process, owing to the complex cellular or protein engineering requirements.
Market Share by Target Indication
Based on the target indications, the global ADC contract manufacturing market is segmented into solid tumors, haematological tumors and others. With the anticipated approval of ADC therapeutics for their primary application in the treatment of solid tumors, this market segment is anticipated to occupy the largest market share in the overall antibody drug conjugates contract manufacturing market.
Market Share by Antibody Generation
Based on the antibody generation, the antibody market is segmented into second generation, third, fourth and next generation. Presently, the market is dominated by revenues generated from manufacturing of third generation antibodies, followed by fourth generation antibodies. This can be attributed to the fact that at present, nearly 40 percent of approved antibody drug conjugates and majority of the clinical stage antibody drug conjugates have third generation ADC component. This trend is unlikely to change in the near future.
Market Share by Antibody Origin
Based on the antibody origin, the antibody market is segmented into humanized, chimeric, murine and others. Currently, the market is primarily driven by ADCs utilizing human origin antibodies. This can be attributed to the fact that fully human origin antibodies have a low risk of generating immune reactions, as compared to murine or chimeric antibodies. It is worth mentioning that the market for chimeric origin ADCs is expected to grow at a relatively high CAGR, owing to their application in early stages of biotherapeutics research, as a more economical alternative to human or humanized antibodies.
Market Share by Type of Antibody Isotype
Based on the type of antibody isotype, the antibody market is segmented into IgG1, IgG4 and others. Presently, the market is dominated by IgG1 antibody isotype. This can be attributed to the fact that IgG1 is the most common isotype available in the serum. Further, it is highly active in eliciting an immune response via the Fc medicated effector function, which is the primary mode of action for tumor targeting therapies.
Market Share by Type of Payload
Based on the type of payload, the HPAPI / payload market is categorized into auristatin, camptothecin, DNA topoisomerase I inhibitor, maytansinoid and others. Presently, the market is dominated by camptothecin as an ADC payload. This can be primarily attributed to the fact that camptothecin-based therapies possess the potential to avoid peripheral neuropathy, which is the most common adverse event associated with auristatin-based therapies. Further, these payloads have higher tolerability, allowing for the administration of higher doses of ADCs, leading to an enhanced therapeutic effect.
It is worth highlighting that the market share for maytansinoid-based ADCs is likely to grow at a higher CAGR in the near future.
Market Share by Type of Linker
Based on the type of linker, the conjugation / linker market is categorized into Maleimide, SMCC, tetrapeptide-based linker, valine-citrulline and others. Presently, the market is dominated by Maleimide as an ADC linker and this trend is unlikely to change in the future as well. This can be attributed to the fact that Maleimide linkers are uncharged and lipophilic, which confers additional stability to the ADC therapeutic.
ADC Contract Manufacturing Market Share by Key Geographical Regions
This segment highlights the distribution of global ADC contract manufacturing market across various geographies, such as North America, Europe, and Asia-Pacific and rest of the world. According to the projections, the antibody drug conjugates contract manufacturing market in North America is likely to capture majority (46%) of the share, and this trend is unlikely to change in the future as well. It is worth highlighting that the market in Europe is expected to grow at a relatively higher CAGR (15%), during the period 2023-2035.
ADC Contract Manufacturing Market Key Insights
The market report features an extensive study of the current market landscape, market size and future opportunities for the companies involved in the ADC contract manufacturers, during the forecast period. Further, the market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key takeaways of the ADC contract manufacturing market report are briefly discussed below.
Overall Market Landscape of ADC Contract Manufacturers: Majority of the Contract Manufacturers are Based in North America
The ADC contract manufacturing market landscape features the presence of 30 large, mid-sized and small companies. Over 45% of the companies were established before 2000, demonstrating extensive experience and expertise in the contract manufacturing industry. Examples of companies, established before 1980 (in alphabetical order) include Lonza, MilliporeSigma, Sartorius and Sterling Pharma Solutions. Further, it is worth highlighting that 50% of the ADC contract manufacturers are based in North America. Within Europe, Switzerland emerged as the hub of ADC contract manufacturers. Notably, 43% of the companies offer all types of manufacturing services related to ADCs. Moreover, industry stakeholders are actively undertaking expansion initiatives for their product / service portfolios to become one-stop shops for mitigating the challenges associated with technology transfer and scale-up.
Key Drivers for ADC Contract Manufacturing Market Growth: Increasing Demand for Antibody Drug Conjugates
The growth of the ADC contract manufacturing market can be attributed to the ever-increasing demand for advanced therapeutic modalities, such as antibody drug conjugates. The ADC therapeutics domain features a rich pipeline of commercialized ADCs. Additionally, a number of ADCs are being evaluated in clinical trials, owing to the highly selective and specific nature of antibody drug conjugates in targeting tumor cells. This demonstrates the extensive development efforts being undertaken by stakeholders in this domain. The anticipated success of these drugs is likely to act as an impetus to the growth of overall ADC contract manufacturing market. It is important to note that ADCs are highly complex and unstable molecules, and require advanced technologies, expertise and manufacturing facilities for their production, which are available with contract manufacturers. Therefore, in recent years, an increased inclination of ADC developers towards outsourcing complex manufacturing operations has been observed, which is unlikely to change in the future.
Market Trend Analysis: Growing Interest in ADC Contract Manufacturing Market is Evident from the Rise in Partnership and Expansion Activity
Several stakeholders have been forging alliances with other industry / non-industry players in ADC contract manufacturing market for manufacturing antibody drug conjugates. It is worth highlighting that, since 2019, more than 30 partnerships have been inked in the industry. Further, the stakeholders are also acquiring other companies specializing in the manufacturing of various ADC components, in order to expand their existing capabilities and consolidate their product / service portfolio. In this context, in June 2023, Lonza acquired Synaffix in order to gain access to the company’s site specific linker technology platform and R&D capabilities.
Owing to the increasing outsourcing of ADC manufacturing process, several players in ADC contract manufacturing market have made significant investments in order to expand their existing facilities or establish new production plants. It is worth highlighting that over 35% of the expansions undertaken since 2019 have been inked in the last two years. Majority of the expansion instances reported in this domain were focused on expanding existing capabilities. Notably, ~91% of the expansions were being undertaken for offering ADC manufacturing services, followed by those being undertaken for offering analytical / development services for ADCs. Some examples of firms involved in the expansion initiatives include (in alphabetical order) Piramal Pharma Solutions and WuXi Biologics. It is interesting to note that more than 65% of the expansions were carried out in Europe, followed by those carried out in North America. As such, the ADC contract manufacturing companies in other regions are also expected to continue to carry out capacity expansions, driving the market growth for ADC contract manufacturing market.
ADC Contract Manufacturing Market Size: Antibody Segment to Hold the Largest Market Share
The global market for ADC contract manufacturing is estimated to be worth $1.79 billion in 2024. Owing to the increase in the outsourcing of ADC manufacturing, the market growth is expected to increase at a CAGR of ~13.8% over the forecast period. It is worth highlighting that, in terms of process component, antibody is expected to capture the majority of the shares of the ADC contract manufacturing market during the forecast period. This can be attributed to the fact that antibody production requires complex protein engineering and cellular approaches, which is a cost and time intensive process.
Regional Analysis: North America and Europe Emerged as the Hub of ADC Contract Manufacturing; Europe to be the Fastest Growing Market
Presently, North America and Europe capture more than 70% of the overall ADC contract manufacturing market size. In fact, in recent years, preference of ADC contract manufacturing in North America has witnessed a tremendous increase owing to the regulatory guidance and early approval for contract manufacturing applications by the Food and Drug Administration (FDA). It is worth highlighting that, in the coming years, owing to the anticipated increase in the establishment of ADC contract manufacturing facilities in Europe, this region is likely to grow at a higher CAGR as compared to other regions.
Key Players in ADC Contract Manufacturing Market
Examples of key ADC contract manufacturing organizations (CMOs) (which have also been profiled in this market report; the complete list of companies is available in the full report) include AbbVie Contract Manufacturing, Abzena, CARBOGEN AMCIS, Catalent Pharma Solutions, Cerbios-Pharma, Formosa Laboratories, GBI, Lonza, MabPlex, Millipore Sigma, Piramal Pharma Solutions, Sterling Pharma Solutions and WuXi Biologics. This market report includes an easily searchable excel database of all the ADC contract manufacturing organizations.
Recent Developments in the ADC Contract Manufacturing Market
Several recent developments have taken place in the field of ADC contract manufacturing. the analyst has outlined some of these recent initiatives below. These developments, even if they took place post the release of the market report, substantiate the overall trends that have been outlined in the ADC contract manufacturing market analysis.
- In October 2023, Lonza entered into a manufacturing agreement with an unnamed partner in order to enhance commercial supplies of its antibody drug conjugates through the addition of two new bioconjugation suites at its manufacturing facility in Visp, Switzerland.
- In October 2023, Lonza entered into an agreement with a major biopharmaceutical partner in order to support handling and filling of antibody drug conjugates for commercial supply through the addition of a new filling line at its facility in Stein, Switzerland.
- In September 2023, WuXi Biologics inked a strategic deal with Mabwell Therapeutics to support and accelerate Mabwell’s ADC research, development and commercialization initiatives.
ADC Contract Manufacturing Market Report Coverage
The ADC contract manufacturing market report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this industry, across different geographies. Amongst other elements, the market research report includes:
- A preface providing an introduction to the full report, ADC Contract Manufacturing Market (6th Edition), Industry Trends and Global Forecasts, till 2035.
- An outline of the systematic research methodology adopted to conduct the study on ADC contract manufacturing market, providing insights on various assumptions, methodologies, and quality control measures employed to ensure accuracy and reliability of the findings.
- An overview of economic factors that impact the overall market outlook, including historical trends, currency fluctuation, foreign exchange impact, recession, and inflation measurement.
- An executive summary of the key insights captured during the research, offering a high-level view of the current landscape of ADC contract manufacturing industry and its likely evolution in the short to mid and long term.
- A general overview on the essential components of ADC therapeutics, the challenges associated with manufacturing of such therapies along with information on the rising trend of contract manufacturing in this segment of biopharmaceutical industry.
- A detailed assessment of the overall market landscape of ADC contract manufacturers, based on several relevant parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, type of ADC manufacturing service offered (antibody manufacturing, HPAPI and payload synthesis, linker manufacturing, conjugation and fill / finish services), type of additional service offered (proof-of-concept studies, process development and scale-up and analytical development), scale of operation (Preclinical, clinical and commercial) and location of manufacturing facility.
- A detailed competitiveness analysis of ADC contract manufacturers, based on manufacturing strength (in terms of scale of operation and number of ADC manufacturing facilities), service strength (in terms of number of ADC services offered, number of additional services offered and location of ADC manufacturing facilities) and supplier strength (in terms of employee count and years of experience in this field).
- Elaborate profiles of ADC contract manufacturers (shortlisted on the basis of competitiveness analysis). Each profile provides a brief overview of the company, its financial information (if available), manufacturing services portfolio (specific to antibody drug conjugates), location of production facilities, and an insightful recent development and future outlook.
- A detailed analysis of the various expansion initiatives undertaken by ADC contract manufacturers, during the period 2019-2023, along with information on several relevant parameters, such as year of expansion, type of expansion, purpose of expansion (manufacturing, analytical / development and fill / finish), scale of operation (preclinical, clinical and commercial), location of expanded facility, type of facility and most active players (based on number of expansion initiatives).
- An analysis of the recent partnerships inked between various ADC contract manufacturers, since 2019, based on several parameters, such as year of partnership, type of partnership (acquisitions, joint ventures, licensing agreements, manufacturing agreements, mergers, product development agreements, product development and manufacturing agreements, research agreements, technology integration agreements and others), purpose of agreement, scale of operation and most active players (in terms of number of partnerships). This section also highlights the regional distribution of partnership activity in this market.
- A qualitative analysis highlighting the various factors that needs to be considered by ADC developers, while deciding whether to manufacture their respective products in-house or outsource the manufacturing operation to contract service providers.
- A detailed discussion on various steps (antibody manufacturing, payload manufacturing, linker manufacturing, conjugation and fill / finish) involved in the manufacturing of ADCs, along with information on the cost requirements across each stage.
- An estimate of the overall ADC manufacturing / bioconjugation capacity (in kilograms) of ADC contract manufacturers based on information provided by various stakeholders in the public domain. The analysis highlights the distribution of global capacity by company size (small, mid-sized and large), key geographical regions (North America, Europe and Asia-Pacific) and key players (in terms of highest bioconjugation capacity).
- An overview of the current market landscape of ADCs, along with detailed analysis of the ADCs pipeline, based on several relevant parameters, such as status of development, target disease indication, therapeutic area, line of treatment, dosing frequency, type of therapy, target antigen, antibody isotype, payload / cytotoxin / warhead, type of payload and type of linker.
- An in-depth analysis of completed and ongoing clinical studies of various antibody drug conjugates, based on several relevant parameters, such as trial registration year, trial status, trial phase, enrolled patient population, type of sponsor / collaborator, target population, study design, most active industry players, and non-industry players (in terms of number of trials) and key geographical regions.
- An in-depth analysis of over 140 ADC therapy developers that are likely to partner with ADC contract manufacturers, based on several relevant parameters, such as developer strength (in terms of company size and its experience), pipeline maturity (in terms of number of drugs in pipeline, their stage of development and type of target indication) and manufacturing capabilities.
- An informed estimate of the annual commercial and clinical demand for ADC therapeutics (in kilograms) based on, based on relevant parameters, such as target patient population, dosing frequency and dose strength of approved products and clinical stage candidates.
- A detailed regional capability assessment framework comparing the key geographies, based on a number of parameters, including the number of ADC contract manufacturers, number of ADC manufacturing facilities, number of facility expansions, installed ADC bioconjugation capacity, number of registered clinical trials and demand for ADCs in that particular geographical region.
- A detailed assessment of the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments, plotted on a 2×2 matrix.
- A detailed ADC contract manufacturing market forecast analysis in order to estimate the existing market size and future opportunity for ADC contract manufacturers over the next 12 years. Based on multiple parameters, likely adoption trends and through primary validations, the analyst has provided an informed estimate on the market size during the forecast period 2024-2035.
- Detailed projections of the current and future opportunity within the ADC contract manufacturing market across different stages of development, such as phase I, phase II, phase III and commercial.
- Detailed projections of the current and future opportunity within antibody drug conjugates contract manufacturing market across different process components, such as antibody, HPAPI / cytotoxic payload, conjugation / linker and fill / finish.
- Detailed projections of the current and future opportunity within the ADC contract manufacturing industry across different target indications, such as solid tumors, hematological tumors and others.
- Detailed projections of the current and future opportunity within the market across different antibody generations, such as second, third, fourth and next generation.
- Detailed projections of the current and future opportunity within the ADC contract manufacturing market across different antibody origins, such as humanized, chimeric, murine and others.
- Detailed projections of the current and future opportunity within the antibody drug conjugates contract manufacturing market across different antibody isotypes, such as IgG1, IgG4 and others.
- Detailed projections of the current and future opportunity within the ADC contract manufacturing market across different types of payloads, such as auristatin, camptothecin, DNA topoisomerase I inhibitor, maytansinoid and others.
- Detailed projections of the current and future opportunity within the market across different types of linkers, such as Maleimide, SMCC, tetrapeptide-based linker, valine-citrulline and others.
- Detailed projections of the current and future opportunity within the ADC contract manufacturing industry across key geographical regions, including North America, Europe, Asia-Pacific and rest of the world.
- Detailed projections of the current and future opportunity within the commercial ADC contract manufacturing market, based on several relevant parameters such as type of component, target indications, type of generation, type of antibody origin, type of antibody isotype, type of payload, type of linker and key geographical regions.
- Detailed projections of the current and future opportunity within the clinical ADC contract manufacturing market, based on several relevant parameters such as phase of development, type of component, target indications, type of antibody origin, type of antibody isotype, type of payload, type of linker and key geographical regions.
- An in-depth analysis of the factors that can impact the growth of ADC contract manufacturing market. It also features identification of key drivers, potential restraints, emerging opportunities, and existing challenges.
One of the key objectives of this market report was to estimate the current market size, opportunity and the future growth potential for the ADC contract manufacturing market, over the forecast period. Based on multiple parameters, likely adoption trends and through primary validations, the analyst has provided an informed estimate on the market evolution during the forecast period.
The ADC contract manufacturing market analysis also features the likely distribution of the current and forecasted opportunity within this market across various segments, such as stage of development (phase I, phase II, phase III and commercial), process component (antibody, HPAPI / cytotoxic payload, conjugation / linker and fill / finish), target indication (Solid Tumors, Hematological Tumors and others), antibody generation (second, third, fourth and next), antibody origin (humanized, chimeric, murine and others), antibody isotype (IgG1, IgG4 and others), type of payload (auristatin, camptothecin, DNA topoisomerase I inhibitor, maytansinoid and others), type of linker (Maleimide, SMCC, tetrapeptide-based linker, valine-citrulline and others), and key geographical regions (North America, Europe, Asia-Pacific and Rest of the World). In order to account for future uncertainties and to add robustness to the model, the analyst has provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in the ADC contract manufacturing market. In addition, the research report features detailed transcripts of interviews held with the following industry stakeholders (arranged on the basis of designation):
- Chief Executive Officer, Large Company, Italy and Technical Business Development Manager, Large Company, Italy
- Chief Executive Officer and Founder, Small Company, UK
- Chief Executive Officer and Co-Founder, Small Company, France
- Former Chief Executive Officer, Large Company, US
- Chief Commercial Officer, Mid-sized Company, Switzerland
- Chief Business Officer, Small Company, Switzerland
- Executive Director, Large Company, Japan and Chief Innovation Officer, Large Company, Japan
- Director, Business Development, Small Company, Netherlands
- Director Corporate Development, Mid-sized Company, US
- Director, Business Development, Large Company, US and Former Group Product Manager, Large Company, US
- Former Director of CDMO, Large Organization, France
- Business Development Manager, Mid-sized Company, Switzerland
- Former Head of Bioconjugates Commercial Development, Large Company, Switzerland
- Former Site Head, Large Company, US
- Associate Scientist, Large Company, US
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Key Benefits of Buying this Report
- The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
- Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
- The report provides stakeholders with a pulse on the ADC Contract Manufacturing Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.
Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.
Table of Contents
Companies Mentioned
- AbbVie
- AbbVie Contract Manufacturing
- ABL Bio
- AbTis
- Abzena
- ACES Pharma
- ADC Biotechnology (Acquired by Sterling Pharma Solutions)
- ADC Therapeutics
- Adcentrx Therapeutics
- AIMEDBIO
- Ajinomoto
- Ajinomoto Bio-Pharma Services
- Almac
- Alphamab Oncology
- ALSA Ventures
- Alteogen
- Ambrx
- Amgen
- Angiex
- Araris Biotech
- Asana BioSciences
- Astellas Pharma
- AstraZeneca
- ATB Therapeutics
- Atreca
- Avipep Therapeutics
- Axplora
- Bayer
- BeiGene
- Bicycle Therapeutics
- Bio-Synthesis
- Bio-Thera Solutions
- BioAtla
- Biocytogen
- BioMed Valley Discoveries
- BiOneCure Therapeutics
- Bioqube Ventures
- Biosion
- BiVictriX Therapeutics
- BOC Sciences
- Bolt Biotherapeutics
- Boostimmune
- Bristol-Myers Squibb
- BSP Pharmaceuticals
- Byondis
- Cambrex
- CARBOGEN AMCIS
- Catalent Pharma Solutions
- Celltrion
- Centrose
- Cerbios-Pharma
- ChemPartner
- Corbus Pharmaceuticals
- Creative Biolabs
- Cristal Therapeutics
- CSPC Pharmaceutical
- CStone Pharmaceuticals
- CureMeta
- CytomX Therapeutics
- Daiichi Sankyo
- Dalton Pharma Services
- Dantari
- Debiopharm
- Diatheva
- Duality Biologics
- Eisai
- Elevation Oncology
- EMD Serono
- Emergence Therapeutics
- Exelixis
- Farmabios
- Formosa Laboratories
- Formosa Pharmaceuticals
- Fortis Therapeutics
- Fosun Pharma
- GBI
- Genentech
- GeneQuantum Healthcare
- Genmab
- Genor Biopharma
- Gilead Sciences
- Glycotope
- GSK
- GTP Bioways
- Hangzhou Adcoris BioPharma
- Hangzhou DAC Biotech
- Harbour BioMed
- Heidelberg Pharma
- Hisun Pharmaceuticals
- Hummingbird Bioscience
- Iconic Therapeutics
- Iksuda Therapeutics
- ImmuneOncia Therapeutics
- ImmunoBiochem
- ImmunoGen
- Immunome
- Innovent Biologics
- IntoCell
- iProgen Biotech
- KLUS Pharma (Subsidiary of Kelun-Biotech)
- Kodiak Sciences
- LaNova Medicines
- LegoChem Biosciences
- Lepu Biopharma
- Levena Biopharma
- Light Chain Bioscience
- Lonza
- Luzsana Biotechnology
- Mablink Bioscience
- MabPlex
- Mabwell (Shanghai) Bioscience
- Mabwell Therapeutics
- MacroGenics
- Magenta Therapeutics
- McSAF
- MediaPharma
- MediLink Therapeutics
- Megalith Pharmaceuticals
- Menarini
- Merck
- Mersana Therapeutics
- MilliporeSigma
- Mitsubishi Tanabe Pharma
- MuseChem
- Mythic Therapeutics
- NanoValent Pharmaceuticals
- Navrogen
- NBE-Therapeutics
- Nordic Nanovector
- NovaRock Biotherapeutics
- Novartis
- Novasep
- NovoCodex Biopharmaceuticals
- OBI Pharma
- OGD2 Pharma
- Oncolinx
- Oncomatryx Biopharma
- OnCusp Therapeutics
- Orano Med
- Oxford BioTherapeutics
- Paul Scherrer Institute
- Peak Bio
- Perseus Proteomics
- Pfizer
- Pheon Therapeutics
- Pierre Fabre
- PinotBio
- Piramal Pharma Solutions
- ProfoundBio
- Pyxis Oncology
- Rakuten Medical
- Recipharm
- Regeneron
- RemeGen
- Sanofi
- Sartorius
- Schengen Pharma
- Seagen
- Shanghai Fudan Zhangjiang Biopharmaceutical
- Shanghai Hansoh Biomedical
- Shanghai Pharmaceuticals
- Singzyme
- Sorrento Therapeutics
- SOTIO Biotech
- Sterling Pharma Solutions
- Sutro Biopharma
- Synaffix
- Syngene
- SystImmune
- Takeda
- Takeda Oncology
- Tanabe Research Laboratories
- Targinta (Subsidiary of Xintela)
- Toray Industries
- TOT BIOPHARM
- TRIO Pharmaceuticals
- Triphase Accelerator
- Tubulis
- UCB
- University Medical Center Groningen
- Vincerx Pharma
- WuXi Biologics
- WuXi STA (A subsidiary of WuXi AppTec)
- Y-Biologics
- Zhejiang Teruisi Pharmaceutical
- Zydus Lifesciences
- Zymework
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 510 |
| Published | May 2024 |
| Forecast Period | 2024 - 2035 |
| Estimated Market Value ( USD | $ 1.79 Billion |
| Forecasted Market Value ( USD | $ 6.87 Billion |
| Compound Annual Growth Rate | 13.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 187 |
